These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27671624)

  • 1. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.
    Kaye J; Piryatinsky V; Birnberg T; Hingaly T; Raymond E; Kashi R; Amit-Romach E; Caballero IS; Towfic F; Ator MA; Rubinstein E; Laifenfeld D; Orbach A; Shinar D; Marantz Y; Grossman I; Knappertz V; Hayden MR; Laufer R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6145-E6152. PubMed ID: 27671624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS.
    Rothhammer V; Kenison JE; Li Z; Tjon E; Takenaka MC; Chao CC; Alves de Lima K; Borucki DM; Kaye J; Quintana FJ
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33408169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis.
    Abdullah A; Maged M; Hairul-Islam M I; Osama I A; Maha H; Manal A; Hamza H
    PLoS One; 2019; 14(4):e0215981. PubMed ID: 31026283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.
    Berg J; Mahmoudjanlou Y; Duscha A; Massa MG; Thöne J; Esser C; Gold R; Haghikia A
    J Neuroimmunol; 2016 Sep; 298():9-15. PubMed ID: 27609269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
    Yang EJ; Stokes JV; Kummari E; Eells J; Kaplan BL
    Toxicol Sci; 2016 May; 151(1):35-43. PubMed ID: 26822306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
    Ruffini F; Rossi S; Bergamaschi A; Brambilla E; Finardi A; Motta C; Studer V; Barbieri F; De Chiara V; Hayardeny L; Comi G; Centonze D; Martino G
    Mult Scler; 2013 Jul; 19(8):1084-94. PubMed ID: 23232603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.
    Wilmes AT; Reinehr S; Kühn S; Pedreiturria X; Petrikowski L; Faissner S; Ayzenberg I; Stute G; Gold R; Dick HB; Kleiter I; Joachim SC
    J Neuroinflammation; 2018 Jun; 15(1):183. PubMed ID: 29903027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
    Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
    J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smek1 deficiency exacerbates experimental autoimmune encephalomyelitis by activating proinflammatory microglia and suppressing the IDO1-AhR pathway.
    Duan RN; Yang CL; Du T; Liu A; Wang AR; Sun WJ; Li X; Li JX; Yan CZ; Liu QJ
    J Neuroinflammation; 2021 Jun; 18(1):145. PubMed ID: 34183017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor.
    Shen PX; Li X; Deng SY; Zhao L; Zhang YY; Deng X; Han B; Yu J; Li Y; Wang ZZ; Zhang Y
    EBioMedicine; 2021 Feb; 64():103227. PubMed ID: 33530002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laquinimod enhances central nervous system barrier functions.
    Lühder F; Kebir H; Odoardi F; Litke T; Sonneck M; Alvarez JI; Winchenbach J; Eckert N; Hayardeny L; Sorani E; Lodygin D; Flügel A; Prat A
    Neurobiol Dis; 2017 Jun; 102():60-69. PubMed ID: 28235673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the mechanism of laquinimod action.
    Brück W; Wegner C
    J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells.
    Rouse M; Singh NP; Nagarkatti PS; Nagarkatti M
    Br J Pharmacol; 2013 Jul; 169(6):1305-21. PubMed ID: 23586923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
    Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
    Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor.
    Singh NP; Hegde VL; Hofseth LJ; Nagarkatti M; Nagarkatti P
    Mol Pharmacol; 2007 Dec; 72(6):1508-21. PubMed ID: 17872969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
    Schulze-Topphoff U; Shetty A; Varrin-Doyer M; Molnarfi N; Sagan SA; Sobel RA; Nelson PA; Zamvil SS
    PLoS One; 2012; 7(3):e33797. PubMed ID: 22479444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.
    Rothhammer V; Mascanfroni ID; Bunse L; Takenaka MC; Kenison JE; Mayo L; Chao CC; Patel B; Yan R; Blain M; Alvarez JI; Kébir H; Anandasabapathy N; Izquierdo G; Jung S; Obholzer N; Pochet N; Clish CB; Prinz M; Prat A; Antel J; Quintana FJ
    Nat Med; 2016 Jun; 22(6):586-97. PubMed ID: 27158906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
    Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
    Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake.
    Gentile A; Musella A; De Vito F; Fresegna D; Bullitta S; Rizzo FR; Centonze D; Mandolesi G
    J Neuroinflammation; 2018 Jan; 15(1):5. PubMed ID: 29304807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
    Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
    Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.